

Running Title: Point prevalence of SARS-CoV-2 in New Orleans

Keywords: SARS Virus, COVID-19, Cross-Sectional Studies, Healthcare Disparities, Prevalence, Seroepidemiologic Studies, New Orleans, Convalescence

Title Point prevalence of SARS-CoV-2 and infection fatality rate in Orleans and Jefferson Parish, Louisiana, May 9-15, 2020

Authors: Amy K Feehan, PhD, Daniel Fort, PhD, MPH, Julia Garcia-Diaz, MD, MSc, FACP, FIDSA, Eboni Price-Haywood, MD, MPH, Cruz Velasco, PhD, Eric Sapp, MDiv, MPP, Dawn Pevey, RN, BSN, MBA, Leonardo Seoane, MD, FACP

Affiliations:

Clinical Infectious Diseases Research, Ochsner Clinic Foundation, New Orleans, LA, USA (A. Feehan)

University of Queensland, Ochsner Clinical School, New Orleans, LA, USA (A. Feehan, J. Garcia-Diaz, E. Price-Haywood, L. Seoane)

Center for Outcomes and Health Services Research, Ochsner Clinic Foundation, New Orleans, LA, USA (D. Fort, E. Price-Haywood, C. Velasco, L. Seoane)

Department of Infectious Diseases, Ochsner Clinic Foundation, New Orleans, LA, USA (J. Garcia-Diaz)

Public Democracy, Arlington, VA, USA (E. Sapp)

Ochsner Health, New Orleans, LA USA (D. Pevey, L. Seoane)

Louisiana State University Health Science Center-Shreveport, Shreveport, LA, USA (L. Seoane)

Abstract - 50

Using a novel recruitment method to reduce selection bias with paired molecular and antibody testing for SARS-CoV-2 infection, we determined point prevalence in a racially diverse municipality. Infections were highly variable by ZIP and differed by race. Overall census-weighted prevalence was 7.8% and the calculated infection fatality rate was 1.63%.

Text – 790

Seroprevalence studies around the world have estimated the spread of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, but none have been performed in New Orleans, Louisiana, USA, an early epicenter of the outbreak. Additionally, COVID-19 has been widely reported to disproportionately affect Black patients. While the absolute number of deaths have been reported by race, we do not know the infection fatality rate (IFR) which requires knowing how many people are at risk (e.g. infected). This study was designed to estimate SARS-CoV-2 infections in Orleans and Jefferson Parishes (O/JP) and the COVID-19 related IFR by race.

The protocol was approved by the Ochsner IRB and designed to enroll and test up to 3,000 subjects at 10 sites throughout O/JP between May 9 and May 15, 2020. To recruit a representative sample for this high-throughput method, a novel two-step system developed by Public Democracy (Arlington, VA) considered more than 50 characteristics, including social determinants of health and US Census population data, to establish a pool of potential participants reflective of the demographics of the Parishes, from which a randomized subset of 150,000 was selected.

Over 25,000 volunteers were recruited from this subset through dynamic, cross-device digital ads. This volunteer pool was stratified by the same attributes and then randomly issued a text message inviting subjects to private testing locations. Invitations were adjusted daily based on response rates to ensure we achieved our *a priori* goals for a representative sample.

Volunteers checked in with a QR code or phone number to discourage walk-ups. Ochsner Health did not turn uninvited people away but excluded these from analysis if they did not fit criteria. Family members of participants (234), or people who lived in ineligible ZIP codes (34) were excluded. Six people withdrew consent. Digital ads, consent forms, and surveys were created in English, Spanish, and Vietnamese. Participants were offered free taxi service to and from the test sites. Verbal consent was electronically documented, and subjects were asked a short list of questions followed by a blood draw and nasopharyngeal (NP) swab.

US Food and Drug Administration-Emergency Use Authorization approved tests were used. Real-time reverse transcriptase polymerase chain reaction (PCR) tests of NP swabs were performed on the Abbott m2000 RealTime system. Qualitative Immunoglobulin G (IgG) blood tests were performed on the ARCHITECT i2000SR. The IgG test meets criteria described by the CDC to yield high positive predictive value, which was validated by Ochsner Health laboratory and by others. (1,2) Study participants with either or both positive tests were assessed as having been infected with SARS-CoV-2. Census-weighted values were calculated for prevalence and seroprevalence. The positive-testing population included early-stage infections (PCR+ only) as well as people recovering (PCR+ and IgG+) and recovered (IgG+ only). Early-stage infections were excluded from IFR estimation as the outcomes of their infections would not yet be registered as official deaths. Therefore, weighted seroprevalence (anyone with an IgG+ result)

was used to calculate “presumed recovered.” IFR was calculated by dividing cumulative deaths by race, reported by the Louisiana Department of Health, by “presumed recovered” individuals.

Among the 2,640 analyzed, the sample was 63.5% female, 61.8% white, average age of 50.6 years, and average household size of 2.55 people. Among the 183 who tested positive, 49% were Black. The raw prevalence of SARS-CoV-2 in the sample population is 6.9% (7.8%, census-weighted) with 2% positive for active viral shedding (PCR+, with or without IgG). By race, prevalence was highest (10.3%) in Black subjects followed by multiracial (9.4%), Asian (6.4%), and white (5.9%). Hispanic prevalence was 7.5%. 2018 population estimates are indicated in Table 1 and multiplied by weighted seroprevalence (percent IgG+) to generate the number of “presumed recovered.” Reported deaths are divided by “presumed recovered” to calculate the IFR, which was 1.63% overall. The IFR was statistically similar for white (1.58%), Black (1.72%), and multiracial (1.40%), but Asian IFR was significantly lower (0.61%). Hispanic deaths are not currently reported for O/JP.

The prevalence of viral shedding (PCR+) and overall SARS-CoV-2 exposure (IgG+) are listed and mapped by ZIP codes across O/JP in Figure 1. Prevalence was highly variable across the map and in some areas >20%.

Prevalence studies help to understand infection spread, especially when testing resources are limited. This representative, high minority enrollment study found an overall prevalence of PCR+ and/or IgG+ tests to be 7.8%. Hispanics and Asians had higher prevalence compared to whites, and this study confirms a recent report of over-representation of Black individuals with COVID-19 infection in the New Orleans area. (4) The overall IFR was 1.63%, which agrees with a recent estimate of 1.3% IFR (0.6%, 2.1%) for the US (3). The similar IFR among most racial

groups indicates that viral spread at least partially explains the increased number of deaths among minorities.

Acknowledgments


The authors would like to especially thank the labs at the Ochsner Medical Center Jefferson Highway Campus for testing and keeping track of research samples; Dan Nichols, marketing technologist at Public Democracy; George Hutter and ReNOLA for their financial support; Sarah Roberts and Gina Mmahat for clinical site management; Samantha Bright, Lyndsey Buckner-Baiamonte, and Ansley Hammons for research site management; Emily Arata for liaising with public leaders; and countless research coordinators, clinical staff, marketing personnel, medical students, and Epic and IT staff for making site testing possible. The Ochsner Health Market Planning and Analysis team designed the maps in Figure 1. The authors thank Kathleen McFadden for her thorough editing and Dr. Mark Roberts for his review. We would also like to acknowledge the New Orleans Mayor's Office, City of New Orleans Office of Public Health, and the New Orleans City Council, especially council members Helena Moreno and Jason Williams for filming a public service announcement to help recruit participants. We also thank Jefferson Parish President Cynthia Lee Sheng and Parish Council for their support.

References

1. Interim Guidelines for COVID-19 Antibody Testing. Centers for Disease Control and Prevention; 2020. <https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html>


2. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al. Performance characteristics of the Abbott Architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho. *J Clin Microbiol.* 2020;JCM.00941-20. doi:10.1128/jcm.00941-20
3. Basu A. Estimating the infection fatality rate among symptomatic COVID-19 cases in the United States. *Health Aff.* 2020; doi:10.1377/hlthaff.2020.00455
4. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among Black patients and white patients with Covid-19. *N Engl J Med.* 2020; doi:10.1056/NEJMsa2011686

Shedding by ZIP



ZIP	N	COVID Shedding (%)	COVID Exposed (%)
70001	88	3 (3.4%)	8 (9.1%)
70002	41	2 (4.9%)	2 (4.9%)
70003	76	0 (0%)	6 (7.9%)
70005	46	2 (4.3%)	3 (6.5%)
70006	28	2 (7.1%)	3 (10.7%)
70053	14	0 (0%)	3 (21.4%)
70056	40	1 (2.5%)	1 (2.5%)
70058	54	2 (3.7%)	5 (9.3%)
70062	16	1 (6.2%)	2 (12.5%)
70065	63	1 (1.6%)	1 (1.6%)
70072	40	0 (0%)	3 (7.5%)
70094	20	0 (0%)	0 (0%)
70112	8	0 (0%)	1 (12.5%)
70113	15	0 (0%)	1 (6.7%)
70114	22	0 (0%)	3 (13.6%)
70115	407	11 (2.7%)	22 (5.4%)
70116	56	0 (0%)	3 (5.4%)
70117	177	2 (1.1%)	8 (4.5%)
70118	82	0 (0%)	3 (3.7%)
70119	144	0 (0%)	5 (3.5%)
70121	32	2 (6.2%)	3 (9.4%)
70122	215	3 (1.4%)	14 (6.5%)
70123	326	7 (2.1%)	19 (5.8%)
70124	198	1 (0.5%)	4 (2%)
70125	35	1 (2.9%)	5 (14.3%)
70126	106	2 (1.9%)	11 (10.4%)
70127	57	3 (5.3%)	7 (12.3%)
70128	104	5 (4.8%)	19 (18.3%)
70129	17	0 (0%)	4 (23.5%)
70130	49	1 (2%)	5 (10.2%)
70131	48	1 (2.1%)	7 (14.6%)

Exposure by ZIP



medRxiv preprint doi: <https://doi.org/10.1101/2020.06.23.20138321>; this version posted June 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Table 1. Prevalence and IFR in Orleans and Jefferson Parish after 7 weeks of an active stay-at-home order.

	Positive n (total)	Number of O/JP Residents ^a	Raw Prevalence % (CI)	Weighted Prevalence ^b % (CI)	Weighted Seroprevalence % (CI)	Presumed recovered ^c	Deaths as of May 16, 2020 ^a	IFR ^d % (CI)
Total	183 (2640)	825,057	6.9 (6.0,8.0)	7.8 (7.76,7.88)	6.86 (6.8,6.91)	56,578	925	1.63 (1.53,1.74)
White	79 (1607)	419,800	4.9 (3.9,6.1)	5.9 (5.78,5.93)	4.5 (4.44,4.58)	18,975	299	1.58 (1.41,1.77)
Black	90 (828)	356,925	10.9 (8.8,13.2)	10.3 (10.19,10.39)	9.8 (9.7,9.9)	34,973	600	1.72 (1.58,1.86)
Asian	9 (130)	29,740	6.9 (3.2,12.7)	6.4 (6.13,6.69)	5.5 (5.2,5.7)	1,629	10	0.61 (0.33,1.14) ^e
Native American	0 (14)	4,088	0	0	0	-	0	-
Pacific Islander	0 (3)	495	0	0	0	-	2	-
Multiracial /other	5 (58)	14,009	8.6 (2.9,19.0)	9.4 (8.96,9.94)	7.1 (6.7,7.6)	1,001	14	1.40 (0.83,2.36)
Hispanic ^f	18 (293)	86,289	6.1 (3.7,9.5)	7.5 (7.30, 7.65)	5.3 (5.16,5.46)	4,582	unknown	-

^a 2018 population estimates and deaths by race reported by ldh.la.gov

^b Census-weighted prevalence of PCR+ and/or IgG+ tests calculated to match 2018 demographics by Parish and then combined.

^c Number of residents multiplied by weighted seroprevalence (IgG+ tests).

^d Infection Fatality Rate (IFR) equals the number of deaths over presumed infections.

^e Significantly lower than white (p=0.0034), Black (p=0.0013) and multiracial (p=0.0467)

^f Hispanic ethnicity is a separate analysis and numbers were not subtracted from race. Hispanic deaths were not reported by the state as of May 16, 2020.